SynthesisCancer treatment reviews2017
Splenic irradiation for splenomegaly: A systematic review.
Synthesis in Cancer treatment reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 51 citations in OpenAlex.
- Galectin-9Aging cell · 2026Article
- Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.Frontiers in oncology · 2026Review
- Tumor-Induced Rewiring of Splenic Niches: from Immune Organ to Cancer Accomplice.International journal of biological sciences · 2026Review
- Magnetic Resonance Imaging Guided Radiation Therapy for Splenomegaly: Clinical Experiences and Technical Tips.Advances in radiation oncology · 2024Article
- Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice.EJHaem · 2023Review
- Radiotherapy for symptom palliation of splenomegaly in patients with haematological malignancies.Molecular and clinical oncology · 2021Article
- Survival after palliative radiation therapy for cancer: The METSSS model.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2021Article
- How we treat mature B-cell neoplasms (indolent B-cell lymphomas).Journal of hematology & oncology · 2021Review
- Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant.OncoTargets and therapy · 2021Review
- Modern management of splenomegaly in patients with myelofibrosis.Annals of hematology · 2020Review
- Identification of a Splenic Marginal Zone Lymphoma Signature: Preliminary Findings With Diagnostic Potential.Frontiers in oncology · 2020Article
- Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy.ACS applied materials & interfaces · 2019Article
- Splenic oligometastasis: Report of a patient successfully treated with stereotactic body radiation therapy.Journal of radiosurgery and SBRT · 2019Article
- Palliative splenic irradiation for symptomatic splenomegaly in non-Hodgkin lymphoma.Ecancermedicalscience · 2018Article
- The senomorphic impact of astaxanthin on irradiated rat spleen: STING, TLR4 and mTOR contributed pathway.International journal of immunopathology and pharmacologyArticle
- Pretransplant Splenic Irradiation in Patients With Myeloproliferative Neoplasms.Advances in radiation oncologyArticle
- The role of bone marrow and spleen irradiation in the development of acute hematologic toxicity during chemoradiation for esophageal cancer.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Splenic irradiation (SI) is a palliative treatment option for symptomatic splenomegaly (i.e. for pain, early satiety, pancytopenia from sequestration) secondary to hematologic malignancies and disorders. The purpose of the current article is to review the literature on SI for hematologic malignancies and disorders, including: (1) patient selection and optimal technique; (2) efficacy of SI; and (3) toxicities of SI. PICOS/PRISMA methods are used to select 27 articles including 766 courses of SI for 486 patients from 1960 to 2016. The most common cancers treated included chronic lymphocytic leukemia and myeloproliferative disorders; the most common regimen was 10Gy in 1Gy fractions over two weeks, and 27% of patients received retreatment. A partial or complete response (for symptoms, lab abnormalities) was obtained in 85-90% of treated patients, and 30% were retreated within 6-12months. There was no correlation between biologically equivalent dose of radiation therapy and response duration, pain relief, spleen reduction, or cytopenia improvement (r
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.